Neurocrine (NBIX) Biosciences announced Crenessity is now commercially available in the United States. Crenessity was recently approved by the U.S. FDA as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Biotech Alert: Searches spiking for these stocks today
- Top 3 Trending Stocks, According to Analysts – 12/18/2024
- Neurocrine announces FDA approval of crenessity
- Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive
- Neurocrine’s Ingrezza shows efficacy in Huntington’s Disease Chorea